Online citations, reference lists, and bibliographies.

Cardiovascular Protection And Blood Pressure Reduction: A Meta-analysis

J. Staessen, J. Wang, L. Thijs
Published 2001 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND Whether antihypertensive drugs offer cardiovascular protection beyond blood pressure lowering has not been established. We aimed to investigate whether pharmacological properties of antihypertensive drugs or reduction of systolic pressure accounted for cardiovascular outcome in hypertensive or high-risk patients. METHODS In a meta-analysis we extracted summary statistics from published reports, and calculated pooled odds ratios for experimental versus reference treatment. We correlated across-trials odd ratios for differences in systolic pressure between groups. FINDINGS We analysed nine randomised trials comparing treatments in 62605 hypertensive patients. Compared with old drugs (diuretics and b-blockers), calcium-channel blockers and angiotensin converting-enzyme inhibitors offered similar overall cardiovascular protection, but calcium-channel blockers provided more reduction in the risk of stroke (13.5%, 95% CI 1.3-24.2, p=0.03) and less reduction in the risk of myocardial infarction (19.2%, 3.5-37.3, p=0.01). Heterogeneity was significant between trials because of high risk of cardiovascular events on doxazosin in one trial, and high risk of stroke on captopril in another; but systolic pressure differed between groups in these two trials by 2-3 mm Hg. Similar systolic differences occurred in a trial of diltiazem versus old drugs, and in three trials of converting-enzyme inhibitor against placebo in high-risk patients. Meta-regression across 27 trials (136124 patients) showed that odds ratios could be explained by achieved differences in systolic pressure. INTERPRETATION Our findings emphasise that blood pressure control is important. All antihypertensive drugs have similar long-term efficacy and safety. Calcium-channel blockers might be especially effective in stroke prevention. We did not find that converting-enzyme inhibitors or a-blockers affect cardiovascular prognosis beyond their antihypertensive effects.
This paper references
10.1016/0895-7061(96)00037-4
Rationale and Design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
B. Davis (1996)
10.1097/00004872-199005000-00001
Isolated systolic hypertension in the elderly.
J. Staessen (1990)
10.1161/01.CIR.97.24.2382
Reactive oxygen species, metalloproteinases, and plaque stability.
M. Davies (1998)
10.1001/jama.1967.03130150084015
Surgery's relevance to an understanding of basic biology. Tissue repair and cellular regeneration.
J. E. Dunphy (1967)
10.1016/S0140-6736(98)04311-6
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
L. Hansson (1998)
10.1056/NEJM199803053381003
The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension.
R. Estacio (1998)
10.1001/ARCHINTE.160.2.211
Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group.
J. Wang (2000)
10.1161/01.HYP.33.6.1476
Update on the systolic hypertension in Europe (Syst-Eur) trial. The Syst-Eur Investigators.
J. Staessen (1999)
10.1097/00004872-199715110-00019
Clinical results of the Verapamil in Hypertension and Atherosclerosis Study
E. A. Rosei (1997)
10.1016/S0140-6736(99)10327-1
Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study
L. Hansson (1999)
An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. European Working Party on High Blood Pressure in the Elderly (EWPHE).
A. Amery (1985)
10.1536/ihj.22.75
Prospective study on the treatment of mild hypertension in the aged.
K. Kuramoto (1981)
10.1056/NEJM200001203420301
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
S. Yusuf (2000)
10.1016/S0140-6736(00)03307-9
Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration.
B. Neal (2000)
10.1136/bmj.317.7160.703
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
M. R. Stearne (1998)
10.1016/S0140-6736(00)02212-1
Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients
M. Flather (2000)
10.1001/jama.1996.03540100029024
Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial.
N. Borhani (1996)
Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack
S. Pinto (2001)
10.1016/S0140-6736(99)07330-4
Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials
J. Staessen (2000)
10.1161/01.CIR.102.15.1748
Long-Term Effects of Cholesterol Lowering and Angiotensin-Converting Enzyme Inhibition on Coronary Atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT)
K. Teo (2000)
10.1016/0002-9343(80)90438-6
Treatment of mild hypertension: a five year controlled drug trial. The Oslo study.
A. Helgeland (1980)
10.1136/bmj.3.5980.434-a
Letter: Breast cancer in young women.
J. Waterhouse (1975)
10.1016/S0735-1097(00)00736-1
Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril.
S. MacMahon (2000)
10.1536/ihj.35.589
Effect of two different therapeutic approaches on total and cardiovascular mortality in a Cardiovascular Study in the Elderly (CASTEL).
E. Casiglia (1994)
10.1016/S0197-2456(01)00176-3
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): clinical center recruitment experience.
J. Wright (2001)
10.1001/jama.1996.03540230036032
Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension
J. Curb (1996)
10.1016/S0140-6736(99)12323-7
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy
Heart Outcomes Prevention Evaluation Study Investigators (2000)
10.1097/00004872-198710000-00009
Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial.
L. Wilhelmsen (1987)
10.1016/S0140-6736(70)91577-1
Hypotensive therapy in stroke survivors.
A. Carter (1970)
Treatment of mild hypertension: results of a ten-year intervention trial.
Smith Wm (1977)
10.1016/S0002-9149(98)00780-2
Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. QUIET Investigators. QUinapril Ischemic Event Trial.
L. Cashin-Hemphill (1999)
10.1136/bmj.317.7160.713
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
M. R. Stearne (1998)
10.1001/jama.1993.03510060059034
Treatment of Mild Hypertension Study: Final Results
J. Neaton (1993)
Characteristics of published, ongoing, and planned outcome trials in hypertension
J. Staessen (1999)
Treatment of mild hypertension. Preliminary results of a two-year feasibility trial.
Perry Hm (1977)
10.1097/00004872-199816110-00014
The Verapamil in Hypertension and Atherosclerosis Study (VHAS): Results of long‐term randomized treatment with either verapamil or chlorthalidone on carotid intima‐media thickness
A. Zanchetti (1998)
10.1161/01.CIR.102.13.1503
Effect of Amlodipine on the Progression of Atherosclerosis and the Occurrence of Clinical Events
B. Pitt (2000)
10.1016/S0140-6736(00)02526-5
Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study
L. Hansson (2000)
10.1016/S0140-6736(85)91783-0
MORTALITY AND MORBIDITY RESULTS FROM THE EUROPEAN WORKING PARTY ON HIGH BLOOD PRESSURE IN THE ELDERLY TRIAL
A. Amery (1985)
10.1016/S0140-6736(00)03306-7
Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials
M. Pahor (2000)
10.1097/00132586-199712000-00060
Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.
J. Curb (1996)
10.1016/0021-9681(66)90128-7
Effects of treatment in hypertension. Results of a controlled study.
F. Wolff (1966)
10.1093/oxfordjournals.bmb.a072892
Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease.
R. Collins (1994)
10.1136/bmj.293.6555.1145
Randomised trial of treatment of hypertension in elderly patients in primary care.
J. Coope (1986)
Letter: Immunotherapy for colorectal cancer.
L. Y. Hsu (1976)
10.1136/bmj.283.6300.1151
Blood pressure reduction in elderly: a randomised controlled trial of methyldopa.
M. Sprackling (1981)
10.1056/NEJM199903043400902
Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension
J. Tuomilehto (1999)
10.1097/00004872-199610000-00013
Shanghai trial of nifedipine in the elderly (STONE).
L. Gong (1996)
10.1001/jama.1986.03370100098025
Antihypertensive treatment with metoprolol or hydrochlorothiazide in patients aged 60 to 75 years. Report from a double-blind international multicenter study.
J. Wikstrand (1986)
10.1161/01.RES.40.1.98
Alterations in Canine Myocardial Excitability during Ischemia
V. Elharrar (1977)
10.1097/00004872-199816120-00016
Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension
L. Liu (1998)
10.1016/S0140-6736(01)06226-2
Blood-pressure lowering for the secondary prevention of stroke
J. Staessen (2001)
10.1038/sj.jhh.1001062
Systolic versus diastolic pressure: paradigm shift or cycle?
JD Swales (2000)
10.1001/jama.283.15.1967
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
B. Davis (2000)
10.1016/S0140-6736(00)02327-8
Early prediction of severity in acute pancreatitis by urinary trypsinogen activation peptide: a multicentre study
J. Neoptolemos (2000)
10.1001/jama.1995.03520420066040
Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure
R. Garg (1995)
10.1161/01.HYP.6.5.774
The Australian therapeutic trial in mild hypertension.
J. Abernethy (1984)
RANDOMIZED DOUBLE-BLIND COMPARISON OF A CALCIUM CHANNEL BLOCKER AND A DIURETIC IN ELDERLY HYPERTENSIVES : A FINAL RESULT OF THE NATIONAL INTERVENTIONAL COOPERATIVE STUDY IN ELDERLY HYPERTENSION (NICS-EH)
I. Kuwajima (2000)
10.1016/S0140-6736(97)05381-6
Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension
J. Staessen (1997)
10.1016/S0140-6736(00)02527-7
Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)
M. Brown (2000)
Why is antihypertensive drug therapy needed in elderly patients with systolodiastolic hypertension?
L. Thijs (1994)
Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High blood pressure in the Elderly (EWPHE) results: sub-group analysis on entry stratification.
A. Amery (1986)
10.1016/0140-6736(91)92589-T
Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
B. Dahlöf (1991)
Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack
S. MacMahon (2001)
10.1007/S11906-000-0022-2
Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone
N. Kaplan (2000)
10.1016/S0140-6736(98)05012-0
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial
L. Hansson (1999)
FRACTURE OF THE FEMORAL NECK.
Zadik Fr (1964)
10.1001/archinte.1995.00430070053006
Implications of small reductions in diastolic blood pressure for primary prevention.
N. Cook (1995)
10.1053/EUHJ.1999.1833
Dihydropyridine calcium-channel blockers for the treatment of hypertensive diabetic patients.
J. Staessen (2000)
10.3109/08037059709062096
The Captopril Prevention Project (CAPPP) in hypertension--baseline data and current status.
L. Hansson (1997)
10.2337/diacare.21.4.597
Outcome Results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in Patients With Hypertension and NIDDM
P. Tatti (1998)



This paper is referenced by
10.1007/978-3-0348-7859-3
Calcium Channel Blockers
T. Godfraind (2004)
10.1353/hpu.2017.0068
Assessment of Hypertension Management and Outcomes at an Indianapolis Student-Run Free Clinic
B. Wahle (2017)
10.1053/J.SCDS.2003.00.028
Stroke outcomes in life
S. Kjeldsen (2003)
10.2165/00023210-200418040-00003
Secondary Prevention of Stroke
H. Koennecke (2004)
10.1007/s11886-003-0103-3
Trials in isolated systolic hypertension: An update
B. Waeber (2003)
UNIVERSIDADE ESTADUAL PAULISTA "JÚLIO DE MESQUITA FILHO" FACULDADE DE CIÊNCIAS FARMACÊUTICAS
C. Araraquara (2005)
10.1161/HYPERTENSIONAHA.107.090068
Central blood pressure measurements and antihypertensive therapy: a consensus document.
E. Agabiti-Rosei (2007)
10.1345/aph.1L024
Efficacy and Safety of Darusentan: A Novel Endothelin Receptor Antagonist
B. Epstein (2008)
10.1097/HJH.0b013e32832c06ef
Stroke risk and antihypertensive drug therapy.
Michael O'Rourke (2009)
10.1007/978-90-313-7372-7_1
1 Hypertensie: definitie en achtergronden
B.J.H. van den Born (2010)
10.2165/11597620-000000000-00000
Antihypertensive Efficacy of the Losartan/Hydrochlorothiazide Combination and its Effect on Plasma B- Type Natriuretic Peptide in Hypertensive Patients Uncontrolled by Angiotensin II Type 1 Receptor Antagonist-Based Therapy
Hiroshi Meno (2012)
10.1007/s00198-014-2787-1
Goal-directed treatment of osteoporosis in Europe
J. Kanis (2014)
10.1253/CIRCJ.CJ-10-1161
Influence of coronary risk factors on coronary events in Japanese high-risk hypertensive patients. - Primary and secondary prevention of ischemic heart disease in a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial-.
K. Ueshima (2011)
10.2169/INTERNALMEDICINE.51.6297
Efficacy and safety of the losartan-hydrochlorothiazide combination tablet in patients with hypertension uncontrolled by angiotensin II receptor antagonist therapy: the Aichi Research on Combination therapy for Hypertension (ARCH) Study.
K. Maeda (2012)
10.2337/dc10-1294
Effect of Adding Pharmacists to Primary Care Teams on Blood Pressure Control in Patients With Type 2 Diabetes
S. Simpson (2010)
10.4155/CLI.10.8
Emerging therapies in the management of hypertensive patients with osteoarthritis
Giorgio Gentile (2011)
10.5005/JP-JOURNALS-10043-0036
Therapeutic Role of Beta-blockers in Hypertension: A Pragmatic Reappraisal
S. Kumar (2016)
10.1016/S0140-6736(06)68238-X
Atenolol and cardiovascular risk: an issue close to the heart
I. Wilkinson (2006)
10.1136/ard.2010.128462
‘Treat to target’: moving targets from hypertension, hyperlipidaemia and diabetes to rheumatoid arthritis
D. Atar (2010)
10.7326/0003-4819-138-7-200304010-00018
Treatment of Hypertension in Type 2 Diabetes Mellitus: Blood Pressure Goals, Choice of Agents, and Setting Priorities in Diabetes Care
S. Vijan (2003)
Cardiovascular control by the biological clock
F. Scheer (2002)
Badania farmakoekonomiczne - subiektywna ocena jakości życia oraz analiza kosztów leczenia nadciśnienia tętniczego w Polsce
Paczkowska Anna (2014)
10.1007/S11906-005-0063-7
Antihypertensive drugs and incidence of type 2 diabetes: Evidence and implications for clinical practice
S. Asfaha (2005)
10.2165/00044011-200525070-00006
Efficacy and Safety of Olmesartan in the Treatment of Mild-to-Moderate Essential Hypertension in Chinese Patients
C. Liau (2005)
10.7812/TPP/14-226
2014 Hypertension Guideline: Recommendation for a Change in Goal Systolic Blood Pressure.
J. Handler (2015)
10.1111/j.1399-3046.2009.01205.x
Hypertension after pediatric cardiac transplantation: detection, etiology, implications and management.
S. L. Roche (2010)
10.1291/HYPRES.27.657
valsartan in elderly isolated systolic hypertension (VALISH) study: rationale and design.
T. Ogihara (2004)
Medical and Surgical Prevention of Stroke
Chin-Shih Fong (2003)
10.1007/S11883-003-0067-1
Are cholesterol-lowering medications and antihypertensive agents preventing stroke in ways other than by controlling the risk factor?
S. Ruland (2003)
10.1016/S0755-4982(04)98729-5
Comment peut évoluer la prise en charge de l'hypertension artérielle : Prévisions de 1974 à 2034
J. Ménard (2004)
10.1007/s10557-008-6143-6
Secondary Prevention of Coronary Disease with ACE Inhibition-does Blood Pressure Reduction with Perindopril Explain the Benefits in EUROPA?
W. Remme (2008)
The Impact of Lifestyle and Cardiovascular Risk Factors in Midlife on the Health-Related Quality of Life among Old Men
A. Strandberg (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar